A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

Inclusion Criteria: * Voluntarily provide written informed consent prior to the conduct of any study related procedures * Male or female, 18-75 years of age * Meet the DSM-IV criteria for current opioid dependence * Females of childbearing potential and fertile males must use a reliable means of contraception Exclusion Criteria: * Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS) * Received treatment for opioid dependence (e.g., methadone, BPN) within the previous 90 days * Current diagnosis of chronic pain requiring opioids for treatment * Candidates for only short term opioid treatment or opioid detoxification therapy * Pregnant or lactating females * Previous hypersensitivity or allergy to BPN or EVA-containing substances or naloxone * Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) * Current history of coagulopathy, and/or anti-coagulant therapy (such as warfarin) * Meet the DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives) * Current use of benzodiazepines other than physician prescribed use * Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate coope…